Search results for: 'deaf captura state 2017'

Microbiome Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Collaboration Deals in Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2025

Precision Medicine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Central Nervous System (CNS) Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2020 to 2025

Autoimmune Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Licensing Deals in Pharmaceuticals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2025

Option and Evaluation Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2025

Biomarker Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Licensing Deals in Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2025

Analyze co-development deals in pharma and biotech from 2016 to 2025. Includes financials, deal terms, and access to actual contracts where available.